A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab

CompletedOBSERVATIONAL
Enrollment

144

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

March 3, 2023

Study Completion Date

March 3, 2023

Conditions
Carcinoma, Non-Small-Cell Lung
Trial Locations (27)

460-0001

Research Site, Nagoya

464-8681

Research Site, Nagoya

470-1192

Research Site, Toyoake

791-0280

Research Site, Matsuyama

373-8550

Research Site, Ōta

060-8648

Research Site, Sapporo

232-0024

Research Site, Yokohama

236-0051

Research Site, Yokohama

241-8515

Research Site, Yokohama

515-8544

Research Site, Matsusaka

981-1293

Research Site, Natori-shi

980-0873

Research Site, Sendai

710-8602

Research Site, Kurashiki

573-1191

Research Site, Hirakata

591-8555

Research Site, Sakai

350-1298

Research Site, Hidaka

362-0806

Research Site, Kitaadachi-gun Ina

411-8777

Research Site, Sunto-gun Nagaizumi

113-8603

Research Site, Bunkyo

113-8677

Research Site, Bunkyo

181-8611

Research Site, Mitaka

811-1395

Research Site, Fukuoka

951-8566

Research Site, Niigata

700-8558

Research Site, Okayama

541-8567

Research Site, Osaka

770-8503

Research Site, Tokushima

641-8510

Research Site, Wakayama

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY